From loss of skin elasticity to hair density, supplements that offer targeted support for GLP-1 users, as well as those that ...
Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...
Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...
A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...
The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...
Digital technologies loom large on the list—from the growing impact of artificial intelligence to the need for tech-enabled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback